Company Focus - Enjie Co., Ltd. plans to acquire 100% equity of Zhongke Hualian, leading to a stock suspension [2] - Canadian Solar Inc. and its controlling shareholder plan to establish a joint venture to adjust their U.S. market operations [3] - Jiarong Technology intends to acquire 100% of Hangzhou Lanan, with stock resuming trading [3] Equity Changes - ST Tianrui's controlling shareholder is planning a change in control, resulting in stock suspension [4] Shareholding Changes & Buybacks - Shanghai Chuangtou intends to reduce its stake in Zhongwei Company by no more than 1% [5] Operations & Performance - China Shenhua's subsidiary successfully completed a 168-hour trial run of its power generation unit, transitioning to commercial operation [6] - Baillie Tianheng received a milestone payment of $250 million from Bristol-Myers Squibb for the iza-bren project [7] - Jiangxi Copper is in the informal offer stage to acquire shares of SolGold Plc [8] - Aorede plans to sign a 635 million yuan computing power procurement agreement [9] - Maiwei Bio's clinical research for 9MW1911 shows significant reductions in acute exacerbation rates for COPD patients [10] - Huayang Co. has launched a high-performance carbon fiber project with an annual production capacity of 200 tons [10] Financing & Capital Increase - Ganfeng Lithium plans to issue $100 million in exchangeable notes to the China-Africa Development Fund [11] Stock Price Fluctuations - Tongyu Communications confirmed normal operations amid stock price fluctuations [12] - Rongji Software reported normal operations despite stock price declines [13] Other - Xianglou New Materials' application for a specific stock issuance has been accepted by the Shenzhen Stock Exchange [15] - JinkoSolar received a prepayment of 220 million yuan for a fire incident at its battery workshop [15] - Dameng Data's general manager has had his detention lifted [15] - Dongpeng Beverage has received approval from the CSRC for its overseas listing [16]

Core Viewpoint - Maiwei Biotech (688062) announced the completion of Phase IIa clinical study for its innovative drug 9MW1911 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) [1] Group 1: Clinical Study Results - The study involved 80 patients with moderate to severe COPD, with a control group of 20 patients receiving a placebo [1] - All dosage groups of 9MW1911 demonstrated good safety and tolerability compared to the placebo [1] - The annualized exacerbation rate of moderate COPD decreased by over 30% at the recommended Phase IIb dose (N=30) compared to the placebo group [1] - The annualized exacerbation rate for severe COPD decreased by over 40% compared to the placebo group [1] - The proportion of patients experiencing severe exacerbations was significantly lower in the treatment group (13.3% vs 35%) compared to the placebo group [1]

Core Viewpoint - Maiwei Biotech (688062.SH) announced the successful completion of Phase IIa clinical trials for its innovative drug 9MW1911 in patients with moderate to severe chronic obstructive pulmonary disease (COPD), demonstrating good safety and tolerability across all dosage groups [1] Group 1: Clinical Research Results - In the recommended dosage for Phase IIb studies, the annual incidence of acute exacerbations in moderate to severe COPD patients was reduced by over 30% compared to the placebo group [1] - The annual incidence of severe acute exacerbations decreased by over 40%, with a significant reduction in the proportion of patients experiencing severe acute exacerbations [1] - The company is actively advancing the Phase IIb clinical research for 9MW1911 in the COPD indication [1]

Core Viewpoint - Maiwei Biotech announced the completion of Phase IIa clinical study for its self-developed anti-ST2 monoclonal antibody (code: 9MW1911) in patients with moderate to severe chronic obstructive pulmonary disease (COPD), demonstrating promising safety and efficacy results compared to placebo [1] Group 1: Clinical Study Results - The Phase IIa study showed that all dosage groups of 9MW1911 exhibited good safety and tolerability, with an overall adverse event rate similar to the placebo group (70% vs 85%) [1] - The annualized rate of acute exacerbations for moderate COPD patients was reduced by over 30% compared to the placebo group at the recommended Phase IIb dose (RP2D) [1] - The annualized rate of severe acute exacerbations was reduced by over 40% compared to the placebo group [1] Group 2: Drug Development Background - 9MW1911 is an innovative monoclonal antibody developed by Maiwei Biotech based on a high-efficiency B lymphocyte screening platform [1] - The drug is classified as a Class 1 therapeutic biological product and binds with high affinity to the ST2 receptor, thereby blocking the IL33/ST2 signaling pathway [1]

Core Viewpoint - Maiwei Biotech (688062.SH) has completed the Phase IIa clinical study of its innovative drug 9MW1911 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD), showing promising safety and efficacy results compared to placebo [1] Group 1: Clinical Study Results - The Phase IIa study involved 80 patients, with 20 in the placebo group [1] - All dosage groups of 9MW1911 demonstrated good safety and tolerability compared to the placebo [1] - The annualized rate of acute exacerbations of COPD decreased with increasing doses of 9MW1911 [1] Group 2: Efficacy Metrics - In the recommended Phase IIb dose (RP2D) study involving 30 patients, the annualized rate of acute exacerbations in moderate COPD patients was reduced by over 30% compared to the placebo group [1] - The annualized rate of severe acute exacerbations decreased by over 40% compared to the placebo group [1] - The proportion of patients experiencing severe acute exacerbations was significantly lower in the treatment group (13.3%) compared to the placebo group (35%) [1] Group 3: Future Developments - The company is actively advancing the Phase IIb clinical study of 9MW1911 for COPD indications [1]

证券代码：688062 证券简称：迈威生物 公告编号：2025-070 迈威（上海）生物科技股份有限公司 自愿披露关于 9MW1911 临床研究进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司就 9MW1911 开展的 IIa 期临床研究（研究代号：9MW1911-C03）为一 项随机、双盲、安慰剂对照、多次给药、剂量递增研究，主要评价 9MW1911 在 既往吸烟的中重度 COPD 受试者中的安全性、耐受性及药代动力学特征，并初 步评价有效性及免疫原性。研究完成入组 80 例，受试者随机接受静脉输注的 9MW1911 注射液（100 mg、300 mg、600 mg、900 mg 四个剂量）或安慰剂，每 4 周给药一次。 结果显示，各组基线特征总体均衡，大多数受试者的基线血嗜酸性粒细胞计 数<300/μL。与安慰剂（N=20）相比，9MW1911 在各剂量组安全且耐受性良好， 总体的不良事件发生率与安慰剂组相似（70% vs 85%），所有受试者的免疫原性 均为阴性，且未发现新的安全性风险信号。药代动力学 ...

国泰海通证券股份有限公司 关于迈威（上海）生物科技股份有限公司 开立、变更部分募集资金专用账户 并重新签订三方及四方监管协议事项的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通证券"或"保荐机构"） 作为迈威（上海）生物科技股份有限公司（以下简称"迈威生物"或"公司"） 首次公开发行股票并上市持续督导保荐机构，根据《证券发行上市保荐业务管理 办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指 引第 11 号——持续督导》《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作》等有关规定，对迈威生物开立、变更部分募集资金专用账户并重 新签订三方及四方监管协议事项进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意迈威（上海）生物科技股份 有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3859 号），公司首 次向社会公开发行人民币普通股 99,900,000 股，每股发行价格为人民币 34.80 元， 募集资金总额为人民币 3,476,520,0 ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-068 二、募集资金专用账户开立情况 迈威（上海）生物科技股份有限公司 关于开立、变更部分募集资金专用账户 并重新签订三方及四方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迈威（上海）生物科技股份有限公司（以下简称"公司"）于 2025 年 11 月 26 日召开第二届董事会第二十五次会议、第二届监事会第二十次会议，审议 通过了《关于开立、变更部分募集资金专用账户并重新签订三方及四方监管协议 的议案》，同意公司及全资子公司上海朗润迈威生物医药科技有限公司（以下简 称"朗润迈威"）和江苏泰康生物医药有限公司（以下简称"泰康生物"）本次 开立、变更部分募集资金专用账户并重新签订三方/四方监管协议，且授权公司 管理层办理此次募集资金专用账户开立、变更并重新签订三方/四方监管协议相 关事宜。保荐机构国泰海通证券股份有限公司（以下简称"国泰海通证券"或"保 荐机构"）对该事项出具了明确同意的核查意见。现将有关情况公告如下： 一、募集资金基本情况 1 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 迈威（上海）生物科技股份有限公司（以下简称"公司"）第二届监事会 第二十次会议通知于 2025 年 11 月 21 日以书面方式送达全体监事，于 2025 年 11 月 26 日以现场结合通讯方式召开。会议由监事会主席楚键先生主持，会议 应到监事 3 人，实到监事 3 人。会议的召集、召开程序和方式符合《公司法》 等法律法规以及《迈威（上海）生物科技股份有限公司章程》（以下简称"公司 章程"）的有关规定，会议决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于开立、变更部分募集资金专用账户并重新签订三方 及四方监管协议的议案》 证券代码：688062 证券简称：迈威生物 公告编号：2025-069 迈威（上海）生物科技股份有限公司 第二届监事会第二十次会议决议公告 表决结果：3 票同意，0 票反对，0 票弃权。 具体内容详见与本公告同日刊登于上海证券交易所网站（www.sse.com.cn） 的《迈威（上海）生物科技股份有限公司关于开立、变更 ...

Core Insights - A new biotechnology company, Lianwei Chuangyuan (Shanghai) Biotechnology Co., Ltd., has been established with a registered capital of 80 million yuan [1] - The company is co-owned by Maiwei Bio (688062) and Shanghai Lianwei Xiechuang Medical Information Consulting Partnership (Limited Partnership) [1] - The business scope includes medical research and experimental development, as well as various technical services and consulting [1] Company Summary - The registered capital of the newly formed company is 80 million yuan [1] - The legal representative of the company is Gui Xun [1] - The company is involved in multiple areas including technology service, development, consulting, exchange, transfer, and promotion [1] Industry Summary - The establishment of this biotechnology company reflects ongoing investment and interest in the medical research and biotechnology sector [1] - The collaboration between established entities like Maiwei Bio and consulting partnerships indicates a trend towards consolidation and resource sharing in the industry [1]